NCT07243132 Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
| NCT ID | NCT07243132 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GFPC Investigation |
| Condition | Metastatic Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-07-02 |
| Primary Completion | 2031-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-07-02 with a primary completion date of 2031-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment. Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study. They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.
Eligibility Criteria
Inclusion Criteria: * Patient over 18 years old * Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance). * Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance Exclusion Criteria: * Difficulties for understanding French * Patients undergoing treatment with cytotoxic chemotherapy * Patients under legal guardianship, under curatorship or tutorship * Insufficient cognitive capacity to answer questions * Inability to obtain data collection (lost to follow-up, patient's refusal for data collection) * Patients refusing the collection of their data (an information sheet will be provided)
Contact & Investigator
Lionel FALCHERO
PRINCIPAL INVESTIGATOR
GFPC
Frequently Asked Questions
Who can join the NCT07243132 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07243132 currently recruiting?
Yes, NCT07243132 is actively recruiting participants. Contact the research team at Alice.MOGENET@ap-hm.fr for enrollment information.
Where is the NCT07243132 trial being conducted?
This trial is being conducted at Aix-en-Provence, France, Angers, France, Avignon, France, Bastia, France and 11 additional locations.
Who is sponsoring the NCT07243132 clinical trial?
NCT07243132 is sponsored by GFPC Investigation. The principal investigator is Lionel FALCHERO at GFPC. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.